Table 1.
PCR primers list.
Fig 1.
a-b: Kidney HIF2 α does not increase in uremic anemia.
Kidney HIF2 α protein (as percentage of actin-corrected concentration) in control and 7 day-bled rats (Fig 1a) and in control and uremic (4 weeks after 5/6 nephrectomy) rats. * p<0.01). The lower panel in each figure shows a representative gel. 6–8 rats were used in each group.
Fig 2.
a-c: Bone marrow (BM) HIF2 α is inappropriately decreased in uremic anemia.
BM HIF2 α protein (depicted as percentage of actin-corrected concentration) increases in 7 day-bled rats (Fig 2a) Vs control. Contrary to that, BM HIF2 α protein decreases in uremic (4 weeks after 5/6 nephrectomy) rats (Fig. 2b). BM HIF2 α mRNA (Fig. 2c) shows a similar pattern. * p<0.01 Vs C. 6–8 rats were used in each group.
Fig 3.
a-b: Bone marrow (BM) EPO protein levels are not increase in uremic anemic rats.
BM EPO protein (depicted as percentage of actin-corrected concentration) increases in 7 day-bled rats Vs control (Fig 3a). Contrary to that, BM EPO protein does not change in uremic (4 weeks after 5/6 nephrectomy) rats (Fig 2b). The lower panel shows a representative gel. 6–8 rats were used in each group.
Fig 4.
a-c: Bone marrow (BM) EPO receptor (EPO-R) decreases in uremic anemia rats.
BM EPO-R protein (depicted as percentage of actin-corrected concentration) is unchanged in 7 day-bled rats Vs controls (Fig. 4a). Contrary to that BM EPO-R protein decreases in uremic (4 weeks after 5/6 nephrectomy) rats (Fig. 4b). BM EPO-R mRNA (Fig. 4c) shows a similar pattern. * p<0.01 Vs C. 6–8 rats were used in each group.
Fig 5.
a-c: Proximal tibia (PT) EPO receptor (EPO-R) decreases in uremic rats, as shown by Western blot (Fig. 5a) and immunohistochemistry (Fig. 5b).
EPO-R protein levels are depicted as a percentage of their actin-corrected concentrations). 6–8 rats were used in each group. * p<0.001 Vs C. Immunohistochemistry shows the epiphyseal growth plate (EGP) and the primary ossification center (POC). Immunostainable EPO-R appears unchanged in the POC but is decreased in the EGP, which includes the proliferative (P) and hypertrophic (H) chondrocytes. The PT lysate was assessed for EPO stimulated STAT5 phosphorylation (Fig. 5c) in control and uremic (CKD) rats. Animals received a single bolus of IV rhEPO (25 U/kg) or saline, 5 minutes prior to sacrifice. The lower panel shows a representative gel. 6–8 rats were used in each group. * p< 0.01 Vs C.
Table 2.
Basic laboratory values in the 2 experiments.